trial summary · NCT07748624
A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period
VEX-AR: Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase 2 Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome, Followed by an Open-Label Extension Period
Trial record from the TrialBase DB dataset, status RECRUITING, condition VEXAS Syndrome, sponsored by Novartis Pharmaceuticals. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this study is to evaluate clinical efficacy and safety of arumakimig (MAS825) compared to placebo in patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) syndrome. In addition, the study will evaluate the long-term efficacy, safety and tolerability of arumakimig in this population.
Source record: https://clinicaltrials.gov/study/NCT07748624
Facts
| registry id | NCT07748624 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | VEXAS Syndrome |
| sponsor | Novartis Pharmaceuticals |
| sponsor class | INDUSTRY |
| enrollment | 120 |
| start date | 2026-10-30 |
| primary completion | 2028-12-26 |
| completion | 2031-04-15 |
| results posted | not reported |
Conditions
- VEXAS Syndrome
Interventions
- Arumakimig
- Placebo
- Oral glucocorticoids
Countries
- Japan
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.